Jean Marie Canan joins Lectra's Board of Directors
Lectra’s Shareholders’ Meeting appointed Jean Marie (“John”) Canan as a new Director, for a period of four years. Jean Marie Canan becomes a member of Lectra’s Audit Committee, Compensation Committee and Strategic Committee.
A Canadian national, at 64, Jean Marie Canan is currently Lead Independent Director and Chairman of the Audit Committee of REV Group, an American company listed on the NYSE; Director and Chairman of the Audit Committee of Acasti Pharma, a Canadian company listed on the NASDAQ and Director of the Angkor Hospital for Children, a leading non-profit pediatric hospital in Cambodia.
Jean Marie Canan, graduated from McGill University in Montreal, Canada and is a Canadian Certified Public Accountant (CPA), began his career at PricewaterhouseCoopers (PwC) in 1978, starting in their Montreal office, and then two years in their Hong Kong office. From 1990 to 2014, he held many ever-increasing positions of responsibility at Merck & Co, Inc. (“Merck”). These included senior roles in finance, strategy development, business development and operations. He was part of a small team that led the acquisition of Schering-Plough by Merck. He also provided operational oversight for most of the Merck group’s joint ventures, including DuPont-Merck, Johnson and Johnson-Merck, Astra-Merck, and Schering-Plough-Merck. Merck’s Executive Committee selected Jean Marie as one of the five senior leaders charged with defining Merck's new strategy in 2006.